Compare Brown-Forman Corporation Class B (BF.B) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Vertex Pharmaceuticals Incorporated — how do they compare? Brown-Forman Corporation Class B trades at $25.18, while Vertex Pharmaceuticals Incorporated trades at $477.46 (market cap $120.89B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.
| BF.B | VRTX | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $529.59 |
52-Week Low | $22.80 | $366.54 |
Market Cap | — | $120.89B |
Enterprise Value | — | $115.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $26.25, up 0.31% on the day, with a bearish technical signal from moving averages but mixed oscillators. Recent earnings show three consecutive beats, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is divided, with a 25% buy rating amid cautious technical indicators.
The stock's outlook is balanced by strong earnings momentum against bearish technicals. Opportunities lie in continued earnings outperformance, while risks include weak technical trends and lack of consensus among analysts. Investors should weigh fundamental strength against near-term price pressure.
Vertex Pharmaceuticals (VRTX) trades at $480.25, down 1.06% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 35.51% net income margin and consistent earnings beats, while the recent $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio with up to $5 billion in peak sales potential.
The outlook remains positive given Wall Street's consensus buy rating and $538 price target, though integration risks from the Crinetics deal and past earnings volatility warrant caution. Revenue growth and margin strength position VRTX for upside, but investors should weigh acquisition execution against competitive and regulatory pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
